Glaukos Co. (NYSE:GKOS) Short Interest Update

Glaukos Co. (NYSE:GKOS - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 3,290,000 shares, a decrease of 5.7% from the March 31st total of 3,490,000 shares. Based on an average daily volume of 669,700 shares, the short-interest ratio is presently 4.9 days.

Glaukos Stock Performance

GKOS stock traded down $1.14 during midday trading on Tuesday, hitting $96.06. 448,849 shares of the stock traded hands, compared to its average volume of 652,939. The stock's fifty day simple moving average is $92.52 and its 200-day simple moving average is $82.10. Glaukos has a 1-year low of $45.38 and a 1-year high of $103.66. The firm has a market cap of $4.82 billion, a P/E ratio of -34.72 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. During the same quarter last year, the business earned ($0.53) EPS. The firm's revenue for the quarter was up 15.7% compared to the same quarter last year. On average, analysts expect that Glaukos will post -2.18 earnings per share for the current year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 474 shares of the company's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the sale, the chief financial officer now owns 54,916 shares of the company's stock, valued at approximately $4,962,758.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares of the company's stock, valued at $5,163,644.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 474 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the sale, the chief financial officer now directly owns 54,916 shares of the company's stock, valued at approximately $4,962,758.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 232,881 shares of company stock valued at $21,965,491. Company insiders own 6.40% of the company's stock.

Institutional Trading of Glaukos

Several institutional investors have recently modified their holdings of GKOS. National Bank of Canada FI purchased a new position in shares of Glaukos in the fourth quarter worth about $46,000. GAMMA Investing LLC purchased a new position in shares of Glaukos in the fourth quarter worth about $55,000. Quadrant Capital Group LLC lifted its stake in shares of Glaukos by 54.8% in the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 329 shares in the last quarter. CWM LLC lifted its stake in shares of Glaukos by 309.5% in the third quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier's stock worth $104,000 after buying an additional 1,046 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Glaukos by 17.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier's stock worth $137,000 after buying an additional 270 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Stifel Nicolaus reaffirmed a "buy" rating and issued a $110.00 price target on shares of Glaukos in a report on Wednesday, April 3rd. Truist Financial reiterated a "buy" rating and issued a $110.00 price objective on shares of Glaukos in a research note on Monday, April 8th. Needham & Company LLC increased their price objective on shares of Glaukos from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Thursday, February 22nd. Mizuho increased their price objective on shares of Glaukos from $85.00 to $100.00 and gave the stock a "neutral" rating in a research note on Thursday, April 11th. Finally, Wells Fargo & Company increased their price objective on shares of Glaukos from $83.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.80.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.